Louis Tumminia, DO
Internal Medicine · Boynton Beach, FLNPI 1902916117
Payments from drug & device makers
Across 229 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$578
- Novo Nordisk$525
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$452
- Bayer$295
- AstraZeneca$258
- Lilly USA, LLC$232
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,439100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 27 | $578 |
| Novo Nordisk | 28 | $525 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $452 |
| Bayer | 11 | $295 |
| AstraZeneca | 17 | $258 |
| Lilly USA, LLC | 11 | $232 |
| Abbott | 11 | $217 |
| AbbVie(2 entities) | 10 | $195 |
| Novartis | 9 | $182 |
| Johnson & Johnson | 9 | $178 |
| Exact Sciences | 7 | $172 |
| GSK | 7 | $133 |
| Merck | 7 | $108 |
| Amgen | 6 | $98 |
| Amarin Pharma, Inc. | 5 | $91 |
| Esperion Therapeutics, Inc. | 5 | $91 |
| Eisai Inc. | 5 | $77 |
| Kowa Pharmaceuticals America, Inc. | 4 | $72 |
| Mylan Specialty L.p. | 3 | $65 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Bausch Health US, LLC | 3 | $44 |
| Astellas Pharma US Inc | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Boehringer Ingelheim | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Coala Life Inc | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Revance Therapeutics, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$4,439 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 145 | $204,221 |
| OzempicSemaglutide | 98 | $129,234 |
| EliquisApixaban | 107 | $118,288 |
| XareltoRivaroxaban | 84 | $111,390 |
| JardianceEmpagliflozin | 51 | $63,129 |
| RybelsusSemaglutide | 30 | $55,122 |
| FarxigaDapagliflozin Propanediol | 36 | $51,813 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $38,900 |
| TrulicityDulaglutide | 14 | $30,685 |
| Repatha SureclickEvolocumab | 20 | $24,692 |
| MyrbetriqMirabegron | 19 | $16,382 |
| RytaryCarbidopa/Levodopa | 11 | $16,226 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $14,043 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $11,791 |
| Lagevrio (Eua)Molnupiravir | 13 | $8,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $232 | $234,905159 claims |
| Novo NordiskOzempic, Rybelsus | $525 | $184,356128 claims |
| PfizerEliquis, Paxlovid | $578 | $121,147118 claims |
| Johnson & JohnsonXarelto | $178 | $111,39084 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $258 | $65,85655 claims |
| Boehringer IngelheimJardiance | $31 | $63,12951 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $16,38219 claims |
| MerckLagevrio (Eua) | $108 | $8,49413 claims |
| AbbVieSynthroid | $195 | $7,34594 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Boynton Beach
- Debra WeinsteinBoynton Beach$14.8M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.